Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Linderane is a sesquiterpene that has been found in L. aggregata.1,2 It inhibits the cytochrome P450 (CYP) isoform CYP2C9 (Ki = 1.26 μM) in an irreversible and NADPH-dependent manner.1 Linderane decreases phosphoenolpyruvate carboxykinase (Pck1) and glucose-6-phosphatase (G6pc) gene expression, cAMP concentration, and CREB phosphorylation, increases phosphodiesterase 3 (PDE3) activity, and inhibits gluconeogenesis in rat primary hepatocytes.2 In vivo, linderane (50 mg/kg twice per day) decreases serum and hepatic triglyceride levels, as well as random-fed and fasting blood glucose levels in ob/ob mice.
WARNING This product is not for human or veterinary use.
1. Mechanism-
2. Linderane suppresses hepatic gluconeogenesis by inhibiting the cAMP/PKA/CREB pathway through indirect activation of PDE 3 via ERK/STAT3. Front. Pharmacol. 9:476, (2018).